Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 23/01/2026 pm IST			5-day change	1st Jan Change
2,130.00 ^DKK	+0.57%		-2.52%	+5.08%

21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
21/01	Genmab Posts Higher Darzalex Net Sales in FY25	MT

Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09

Published on 06/10/2024 at 06:50 pm IST

S&P Capital IQ

Presenter Speech
Rajan Sharma (Analysts)

Good morning, everyone. Thanks for joining. My name is Rajan Sharma. I cover European Biotech and Pharma for Goldman Sachs, including Genmab. I'm very happy

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
21/01	Genmab Posts Higher Darzalex Net Sales in FY25	MT
21/01	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025	CI
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025 (Update)	FW
21/01	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025	FW
21/01	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
20/01	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
19/01	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
19/01	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
19/01	Genmab's Epcoritamab Improves Progression-free Survival in Lymphoma Patients, Phase 3 Data Shows	MT
17/01	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
17/01	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
17/01	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
17/01	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
17/01	Genmab says phase 3 trial for epcoritamab did not reach statistical significance	RE
17/01	Genmab's blood cancer drug fails main goal in late-stage study	RE
16/01	Genmab Stock Trading Halted, Pending Material News Release	MT
15/01	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
14/01	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
07/01	Genmab partners with Anthropic to accelerate research and development through agentic AI	RE
07/01	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT